Riccardo Candido, ADA 2022: Intensification strategies following GLP1-RA therapy failure in type 2 diabetes, the RESTORE-G real-world study

The RESTORE-G real-world study investigated the intensification strategies following GLP1-RA therapy failure in type 2 diabetes. Dr Riccardo Candido (Diabetes Center District 4, ASUGI, Trieste, Italy) discusses the design of the study, the key findings and the implications for clinical practice.

The abstract entitled ‘Treatment Intensification after Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes—The RESTORE-G Real-World Study’ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.

Questions: 

1. How did the RESTORE-G real-world study investigate intensification strategies following GLP1-RA therapy failure? (0:22)
2. What were the key findings of the study including the main intensification approaches and clinical outcomes with these approaches? (1:57)
3. In your opinion, what are the implications of these results for clinical practice? (4:35)

Disclosures: Riccardo Candido has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.

Filmed as a highlight of ADA 2022.